NTII example: $7,000 per patient, done with Quintiles, the largest CRO in the world. This is from a letter that was sent by Ntii Ceo to shareholders few months ago (if I remember correctly). The study was the phase IIb of Memantine for neuropathic pain. The trauma study is more complex,and longer follow up is 6 months.
Calculate roughly $20,000 per 900 patients = $18,000,000
Probably Pharmos could go alone for the first 300 plus patients, $7.5 M from investors, $3M from the eye drops business assuming the same sales from last year.
The study will last 18 month to 36 months, enough time to get even to maybe even 600 patients.
No need for big partner to provide the money, except that if the results are not the expected good outcome, Pharmos loss all this money, and the private placement money investors will loss money, unless the Alrex/Lotemax/L-tobra money is flowing enough to pay and justify a hefty stock market value, some $4 to $7 per share.
If good results Pharmos is ready for big royalties, 30% to 50% and big payoff for investors.
Pharmos number of employees is not important. Ntii completed last two studies with 6 employees. |
